Oprozomib
Oprozomib (ONX 0912) is an orally bioavailable proteasome inhibitor that selectively targets the CT-L activity of the 20S proteasome subunits β5 (IC50=36 nM) and LMP7 (IC50=82 nM) . It exhibits antineoplastic activity and has been investigated in preclinical in vitro and in vivo studies for hematological malignancies and solid tumors.
Product Specifications
CAS Number
935888-69-0
Product Name Alternative
Orally, Oprozomib, ONX 0912, ONX0912, ONX-0912, immunoproteasome LMP7, inhibit, Inhibitor, epoxyketone, bioavailable, apoptosis, Autophagy, 20S proteasome, PR047, PR-047, PR 047, Proteasome
Field of Research
Cell Biology, Protein Biochemistry
Purity
98.00% (May vary between batches)
Solubility
H2O:< 1 mg/mL (insoluble or slightly soluble) ;10% DMSO+40% PEG300+5% Tween 80+45% Saline:3.3 mg/mL (6.2 mM) ; DMSO:93 mg/mL (174.61 mM) ; Ethanol:< 1 mg/mL (insoluble or slightly soluble)
Smiles
COC[C@H] (NC (=O) [C@H] (COC) NC (=O) c1cnc (C) s1) C (=O) N[C@@H] (Cc1ccccc1) C (=O) [C@@]1 (C) CO1
Molecular Formula
C25H32N4O7S
Molecular Weight
532.61
Storage Conditions
-20°C
Notes
For research use only.
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
E3371-02P-ML550 100 µL
EphB2, NT (Ephrin Type-B Receptor 2, Tyrosine-protein Kinase Receptor EPH-3, DRT, Receptor Protein-Tyrosine Kinase HEK5, ERK, EPH-like Kinase 5, EK5, Tyrosine-protein Kinase TYRO5, Renal Carcinoma Antigen NY-REN-47, DRT, EPHT3, EPTH3, ERK, HEK5, TYRO5) (MaxLight 550) discontinued
Sign In for Pricing
View Details